Sumitomo Pharma America Says Nuvisertib (TP-3654) Gets EMA Orphan Drug Status For Treating Myelofibrosis
ReutersJul 30, 2025 5:36 PM
July 30 (Reuters) - Sumitomo Pharma Co Ltd 4506.T:
SUMITOMO PHARMA AMERICA ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY HAS GRANTED ORPHAN DRUG DESIGNATION TO NUVISERTIB (TP-3654) FOR THE TREATMENT OF MYELOFIBROSIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Cathie Wood’s ARKK Surges 54% in 3 Months — Is Crypto the Main Investment Theme of 2025?
TradingKey - Crypto stocks are getting their groove back, and Cathie Wood isn’t missing a beat. Over the past three months, ARK Innovation ETF (ARKK), ARK Invest’s flagship fund, has surged more than 54%. In June alone, it gained a whopping 23%, making it one of the best-performing U.S. growth ETFsTradingKey
3 hours ago
What to Expect From Microsoft Q4 FY2025 Earnings: The King of AI Monetization — A $4 Trillion Market Cap Within Reach?
TradingKey - Cloud giant Microsoft (MSFT.US) will report its fiscal fourth-quarter 2025 earnings (calendar Q2) after the U.S. market close on July 30. Wall Street is bullish, expecting strong results from Azure cloud services and AI-driven growth to propel Microsoft’s market capitalization towardTradingKey
Wed, Jul 30
U.S. GDP, PCE, and Fed Rate Decision Preview: U.S. Stocks May Continue to Rise
TradingKey - The United States is set to release its latest GDP and PCE data on 30–31 July 2025, with the Federal Reserve’s interest rate decision expected concurrently. Market consensus anticipates that the annualized real GDP growth rate for the second quarter will turn positiveTradingKey
Tue, Jul 29
What to Expect From Meta Q2 Earnings: AI Push, Ad Strength — But Can Profitability Hold?
TradingKey - Meta Platforms (META), the parent company of Facebook, Instagram, and WhatsApp, will release its Q2 2025 earnings after the U.S. market close on Wednesday, July 30. After nine consecutive quarters of beating expectations, analysts expect another strong performance — driven by AI-poweredTradingKey
Tue, Jul 29
Tradingkey
